Article Figures & Data
Figures
- FIGURE 1.
(A) Pretherapy and posttherapy 18F-FDG PET/CT scans for patients showing a CMR to BR. (B) Pretherapy and posttherapy scans for patients without CMR (partial response) after BR.
- FIGURE 2.
Changes in DS from baseline (x-axis) to posttreatment (y-axis) with no. of patients in each category. Responders improved so that posttreatment scans showed at most uptake ≤ uptake by the liver with no new areas representing new disease (DS 3).
- FIGURE 3.
Kaplan–Meier analysis of PFS for patients treated with BR by metabolic response.
- FIGURE 4.
Kaplan–Meier analysis of DOR for patients treated with BR by metabolic response.
- FIGURE 5.
Kaplan–Meier analysis of overall response for patients treated with BR by metabolic response.
Tables
Variable Baseline data Mean age (y) 68 (range, 52–78) Sex (n) Male 22 (69%) Female 10 (31%) Lymphoma status (n) Relapsed 17 (53%) Refractory 15 (47%) MIPI (n) ≤3 (low risk) 17 (53%) 4–5 (intermediate risk) 9 (28%) ≥6 (high risk) 6 (19%) Mean MIPI ± SD 3.78 ± 1.60 Presence of B symptoms (n) 7 (22%) Previous cancer surgery (n) 8 (25%) Previous radiation therapy (n) 6 (19%) Previous chemotherapy (n) Prior rituximab 32 (100%) Prior alkylator 31 (97%) Response to the most recent rituximab-based chemotherapy (n) Complete 16 (50%) Partial 6 (19%) Stable disease 4 (13%) Progressive disease 5 (16%) Not available 1 (3%) Cyclin D1 status (n) Positive 17 (53%) Negative 8 (25%) Not available 7 (22%) LDH level (n) <250 IU/L 20 (63%) 250–450 IU/L (reference range) 4 (13%) >450 IU/L 7 (22%) Not available 1 (3%) β2-microglobulin level (n) 1.1–2.8 mg/L (reference range) 31 (97%) >2.8 mg/L 1 (3%) LDH = lactate dehydrogenase.
18F-FDG PET results Variable CMR (n = 24) Non-CMR (n = 8) Total (n = 32) DS at baseline (n) 4 8 (33) 1 (13) 9 (28) 5 16 (67) 7 (88) 23 (72) DS at cycle 6 (n) 1 8 (33) 0 8 (25) 2 13 (54) 0 13 (41) 3 3 (13) 0 3 (9) 4 0 4 (50) 4 (13) 5 0 4 (50) 4 (13) Response by baseline variables (n) Relapsed disease* 15 (88) 2 (12) 17 (53) Refractory disease* 9 (60) 6 (40) 15 (47) MIPI category (n) ≤3* 15 (88) 2 (12) 17 (53) 4–5* 5 (56) 4 (44) 9 (28) >5* 4 (67) 2 (33) 6 (19) ↵* Percentage based on category total.
Data in parentheses are percentages.
18F-FDG PET results Variable CMR (n = 24) Non-CMR (n = 8) Total (n = 32) IWG best overall response on treatment (n) Complete response 14 (58) 0 14 (44) Partial response 8 (33) 6 (75) 14 (44) Stable disease 1 (4) 2 (25) 3 (9) Progressive or relapsed disease 1 (4) 0 1 (3) IWG best response by the end of cycle 3 (n) Complete response 3 (13) 0 3 (9) Partial response 17 (71) 6 (75) 23 (72) Stable disease 3 (13) 2 (25) 5 (16) Not evaluated 1 (4) 0 1 (3) IWG best response by the end of cycles 3 and 6 (n) Complete response 15 (63) 0 15 (47) Partial response 8 (33) 6 (75) 14 (44) Stable disease 0 2 (25) 2 (6) Not evaluated 1 (4) 0 1 (3) IWG best overall response through 3-y follow-up* (n) Complete response 18 (75) 0 18 (57) Partial response 5 (21) 6 (75) 11 (34) Stable disease 0 2 (25) 2 (6) Progressive or relapsed disease 1 (4) 0 1 (3) ↵* New lymphoma treatments permitted during follow-up.
Data in parentheses are percentages.
Metabolic response IWG best overall response Variable CMR (n = 24) Non-CMR (n = 8) CR + PR (n = 29) CR (n = 18) Stable disease, progressive disease, or relapsed disease (n = 3) PFS Median (95% CI) (mo) 23.8 (17.2–41.5) 10.7 (5.4–11.8) 22.1 (16.2–38.4) 38.4 (16.4–42.9) 5.4 (2.4–11.8) Kaplan–Meier estimate at 12 mo (no. at risk) 91.48 (21) 12.50 (1) 78.57 (22) 100.00 (17) 0.00 (0) DOR Median (95% CI) (mo) 20.6 (14.6–38.8) 7.8 (4.9–14.3) 17.0 (13.3–35.5) 35.5 (13.8–40.3) NA Kaplan–Meier estimate at 12 mo (no. at risk) 86.36 (18) 16.67 (1) 71.43 (19) 88.24 (15) NA OS Median (95% CI) (mo) NR (32.1–NR) 14.2 (8.6–18.8) NR (28.9–NR) NR (32.1–NR) 16.1 (8.6–NR) Kaplan–Meier estimate at 12 mo (no. at risk) 100.00 (23) 50.00 (4) 89.29 (25) 100.00 (17) 66.67 (2) CI = confidence interval; NA = not applicable; NR = not reached.
Supplemental Data
Files in this Data Supplement:
